Imaging with radiolabelled anti-membrane type 1 matrix metalloproteinase (MT1-MMP) antibody: potentials for characterizing atherosclerotic plaques | springermedizin.de

Springer Medizin

nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

01.11.2010 | Original Article

Imaging with radiolabelled anti-membrane type 1 matrix metalloproteinase (MT1-MMP) antibody: potentials for characterizing atherosclerotic plaques

verfasst von: Yuji Kuge, Nozomi Takai, Yuki Ogawa, Takashi Temma, Yan Zhao, Kantaro Nishigori, Seigo Ishino, Junko Kamihashi, Yasushi Kiyono, Masashi Shiomi, Hideo Saji

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 11/2010

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Membrane type 1 matrix metalloproteinase (MT1-MMP) activates pro-MMP-2 and pro-MMP-13 to their active forms and plays important roles in the destabilization of atherosclerotic plaques. This study sought to determine the usefulness of ^99mTc-labelled monoclonal antibody (mAb), recognizing MT1-MMP, for imaging atherosclerosis in a rabbit model (WHHLMI rabbits).

Methods

Anti-MT1-MMP monoclonal IgG₃ and negative control IgG₃ were radiolabelled with ^99mTc after derivatization with 6-hydrazinonicotinic acid (HYNIC) to yield ^99mTc-MT1-MMP mAb and ^99mTc-IgG₃, respectively. WHHLMI and control rabbits were injected with these radio-probes. The aorta was removed and radioactivity was measured at 24 h after the injection. Autoradiography and histological studies were performed.

Results

^99mTc-MT1-MMP mAb accumulation in WHHLMI rabbit aortas was 5.4-fold higher than that of control rabbits. Regional ^99mTc-MT1-MMP mAb accumulation was positively correlated with MT1-MMP expression (r = 0.59, p < 0.0001), while ^99mTc-IgG₃ accumulation was independent of MT1-MMP expression (r = 0.03, p = NS). The highest ^99mTc-MT1-MMP mAb accumulation was found in atheromatous lesions (4.8 ± 1.9, %ID×BW/mm² × 10²), followed in decreasing order by fibroatheromatous (1.8 ± 1.3), collagen-rich (1.6 ± 1.0) and neointimal lesions (1.5 ± 1.5). In contrast, ^99mTc-IgG₃ accumulation was almost independent of the histological grade of lesions.

Conclusion

Higher ^99mTc-MT1-MMP mAb accumulation in grade IV atheroma was shown in comparison with neointimal lesions or other more stable lesions. Nuclear imaging with ^99mTc-MT1-MMP mAb, in combination with CT and MRI, could provide new diagnostic imaging capabilities for detecting vulnerable plaques, although further investigations to improve target to blood ratios are strongly required.

Anzeige

1.

Kolodgie FD, Virmani R, Burke AP, Farb A, Weber DK, Kutys R, et al. Pathologic assessment of the vulnerable human coronary plaque. Heart 2004;90:1385–91.CrossRefPubMed

2.

Lendon C, Born GV, Davies MJ, Richardson PD. Plaque fissure: the link between atherosclerosis and thrombosis. Nouv Rev Fr Hematol 1992;34:27–9.PubMed

3.

Ruberg FL, Leopold JA, Loscalzo J. Atherothrombosis: plaque instability and thrombogenesis. Prog Cardiovasc Dis 2002;44:381–94.CrossRefPubMed

4.

Davies JR, Rudd JH, Weissberg PL. Molecular and metabolic imaging of atherosclerosis. J Nucl Med 2004;45:1898–907.PubMed

5.

Jaffer FA, Libby P, Weissleder R. Molecular and cellular imaging of atherosclerosis: emerging applications. J Am Coll Cardiol 2006;47:1328–38.CrossRefPubMed

6.

Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res 2002;90:251–62.PubMed

7.

Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994;94:2493–503.CrossRefPubMed

8.

Jones CB, Sane DC, Herrington DM. Matrix metalloproteinases: a review of their structure and role in acute coronary syndrome. Cardiovasc Res 2003;59:812–23.CrossRefPubMed

9.

Brown DL, Hibbs MS, Kearney M, Loushin C, Isner JM. Identification of 92-kD gelatinase in human coronary atherosclerotic lesions. Association of active enzyme synthesis with unstable angina. Circulation 1995;91:2125–31.PubMed

10.

Li Z, Li L, Zielke HR, Cheng L, Xiao R, Crow MT, et al. Increased expression of 72-kd type IV collagenase (MMP-2) in human aortic atherosclerotic lesions. Am J Pathol 1996;148:121–8.PubMed

11.

Davies JR, Rudd JH, Weissberg PL, Narula J. Radionuclide imaging for the detection of inflammation in vulnerable plaques. J Am Coll Cardiol 2006;47:C57–68.CrossRefPubMed

12.

Hartung D, Schäfers M, Fujimoto S, Levkau B, Narula N, Kopka K, et al. Targeting of matrix metalloproteinase activation for noninvasive detection of vulnerable atherosclerotic lesions. Eur J Nucl Med Mol Imaging 2007;34:S1–8.CrossRefPubMed

13.

Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 2003;92:827–39.CrossRefPubMed

14.

Sato H, Takino T, Okada Y, Cao J, Shinagawa A, Yamamoto E, et al. A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 1994;370:61–5.CrossRefPubMed

15.

Knäuper V, Bailey L, Worley JR, Soloway P, Patterson ML, Murphy G. Cellular activation of proMMP-13 by MT1-MMP depends on the C-terminal domain of MMP-13. FEBS Lett 2002;532:127–30.CrossRefPubMed

16.

Kuge Y, Takai N, Ishino S, Temma T, Shiomi M, Saji H. Distribution profiles of membrane type-1 matrix metalloproteinase (MT1-MMP), matrix metalloproteinase-2 (MMP-2) and cyclooxygenase-2 (COX-2) in rabbit atherosclerosis: comparison with plaque instability analysis. Biol Pharm Bull 2007;30:1634–40.CrossRefPubMed

17.

Rajavashisth TB, Xu XP, Jovinge S, Meisel S, Xu XO, Chai NN, et al. Membrane type 1 matrix metalloproteinase expression in human atherosclerotic plaques: evidence for activation by proinflammatory mediators. Circulation 1999;99:3103–9.PubMed

18.

Stawowy P, Meyborg H, Stibenz D, Borges Pereira Stawowy N, Roser M, Thanabalasingam U, et al. Furin-like proprotein convertases are central regulators of the membrane type matrix metalloproteinase-pro-matrix metalloproteinase-2 proteolytic cascade in atherosclerosis. Circulation 2005;111:2820–7.CrossRefPubMed

19.

Shiomi M, Ito T, Yamada S, Kawashima S, Fan J. Development of an animal model for spontaneous myocardial infarction (WHHLMI rabbit). Arterioscler Thromb Vasc Biol 2003;23:1239–44.CrossRefPubMed

20.

Abrams MJ, Juweid M, tenKate CI, Schwartz DA, Hauser MM, Gaul FE, et al. Technetium-99m-human polyclonal IgG radiolabeled via the hydrazino nicotinamide derivative for imaging focal sites of infection in rats. J Nucl Med 1990;31:2022–8.PubMed

21.

Ono M, Arano Y, Mukai T, Uehara T, Fujioka Y, Ogawa K, et al. Plasma protein binding of (99m)Tc-labeled hydrazino nicotinamide derivatized polypeptides and peptides. Nucl Med Biol 2001;28:155–64.CrossRefPubMed

22.

Ono M, Arano Y, Uehara T, Yasushi F, Kazuma O, Namba S, et al. Intracellular metabolic fate of radioactivity after injection of technetium-99m-labeled hydrazino nicotinamide derivatized proteins. Bioconjug Chem 1999;10:386–94.CrossRefPubMed

23.

Larsen SK, Solomon HF, Caldwell G, Abrams MJ. [99mTc]tricine: a useful precursor complex for the radiolabeling of hydrazinonicotinate protein conjugates. Bioconjug Chem 1995;6:635–8.CrossRefPubMed

24.

Ishii K, Kita T, Kume N, Nagano Y, Kawai C. Uptake of acetylated LDL by peritoneal macrophages obtained from normal and Watanabe heritable hyperlipidemic rabbits, an animal model for familial hypercholesterolemia. Biochim Biophys Acta 1988;962:387–9.PubMed

25.

Stary HC, Chandler AB, Dinsmore RE, Fuster V, Glagov S, Insull Jr W, et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation 1995;92:1355–74.PubMed

26.

Stary HC, Chandler AB, Glagov S, Guyton JR, Insull Jr W, Rosenfeld ME, et al. A definition of initial, fatty streak, and intermediate lesions of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation 1994;89:2462–78.PubMed

27.

Kobayashi S, Inoue N, Ohashi Y, Terashima M, Matsui K, Mori T, et al. Interaction of oxidative stress and inflammatory response in coronary plaque instability: important role of C-reactive protein. Arterioscler Thromb Vasc Biol 2003;23:1398–404.CrossRefPubMed

28.

Ishino S, Kuge Y, Takai N, Tamaki N, Strauss HW, Blankenberg FG, et al. 99mTc-Annexin A5 for noninvasive characterization of atherosclerotic lesions: imaging and histological studies in myocardial infarction-prone Watanabe heritable hyperlipidemic rabbits. Eur J Nucl Med Mol Imaging 2007;34:889–99.CrossRefPubMed

29.

Shiomi M, Ito T, Hirouchi Y, Enomoto M. Stability of atheromatous plaque affected by lesional composition: study of WHHL rabbits treated with statins. Ann N Y Acad Sci 2001;947:419–23.CrossRefPubMed

30.

Yun M, Yeh D, Araujo LI, Jang S, Newberg A, Alavi A. F-18 FDG uptake in the large arteries: a new observation. Clin Nucl Med 2001;26:314–9.CrossRefPubMed

31.

Zhao Y, Kuge Y, Zhao S, Morita K, Inubushi M, Strauss HW, et al. Comparison of 99mTc-annexin A5 with 18F-FDG for the detection of atherosclerosis in ApoE-/- mice. Eur J Nucl Med Mol Imaging 2007;34:1747–55.CrossRefPubMed

32.

Ogawa M, Ishino S, Mukai T, Asano D, Teramoto N, Watabe H, et al. (18)F-FDG accumulation in atherosclerotic plaques: immunohistochemical and PET imaging study. J Nucl Med 2004;45:1245–50.PubMed

33.

Ishino S, Mukai T, Kuge Y, Kume N, Ogawa M, Takai N, et al. Targeting of lectinlike oxidized low-density lipoprotein receptor 1 (LOX-1) with 99mTc-labeled anti-LOX-1 antibody: a potential agent for imaging of vulnerable plaque. J Nucl Med 2008;49:1677–85.CrossRefPubMed

34.

Huhalov A, Chester KA. Engineered single chain antibody fragments for radioimmunotherapy. Q J Nucl Med Mol Imaging 2004;48:279–88.PubMed

35.

Sharkey RM, Karacay H, Cardillo TM, Chang CH, McBride WJ, Rossi EA, et al. Improving the delivery of radionuclides for imaging and therapy of cancer using pretargeting methods. Clin Cancer Res 2005;11:7109s–21.CrossRefPubMed

36.

Watabe H, Ikoma Y, Kimura Y, Naganawa M, Shidahara M. PET kinetic analysis–compartmental model. Ann Nucl Med 2006;20:583–8.CrossRefPubMed

37.

Darambara DG, Todd-Pokropek A. Solid state detectors in nuclear medicine. Q J Nucl Med 2002;46:3–7.PubMed

38.

Campean V, Neureiter D, Varga I, Runk F, Reiman A, Garlichs C, et al. Atherosclerosis and vascular calcification in chronic renal failure. Kidney Blood Press Res 2005;28:280–9.CrossRefPubMed

39.

Santoliquido A, Di Campli C, Miele L, Gabrieli ML, Forgione A, Zocco MA, et al. Hepatic steatosis and vascular disease. Eur Rev Med Pharmacol Sci 2005;9:269–71.PubMed

40.

Beekman F, van der Have F. The pinhole: gateway to ultra-high-resolution three-dimensional radionuclide imaging. Eur J Nucl Med Mol Imaging 2007;34:151–61.CrossRefPubMed

41.

Akizawa H, Arano Y. Altering pharmacokinetics of radiolabeled antibodies by the interposition of metabolizable linkages. Metabolizable linkers and pharmacokinetics of monoclonal antibodies. Q J Nucl Med 2002;46:206–23.PubMed

42.

Temma T, Sano K, Kuge Y, Kamihashi J, Takai N, Ogawa Y, et al. Development of a radiolabeled probe for detecting membrane type-1 matrix metalloproteinase on malignant tumors. Biol Pharm Bull 2009;32:1272–7.CrossRefPubMed

43.

Rogers BE, Anderson CJ, Connett JM, Guo LW, Edwards WB, Sherman EL, et al. Comparison of four bifunctional chelates for radiolabeling monoclonal antibodies with copper radioisotopes: biodistribution and metabolism. Bioconjug Chem 1996;7:511–22.CrossRefPubMed

44.

Sugimoto K, Nishimoto N, Kishimoto T, Yoshizaki K, Nishimura T. Imaging of lesions in a murine rheumatoid arthritis model with a humanized anti-interleukin-6 receptor antibody. Ann Nucl Med 2005;19:261–6.CrossRefPubMed

45.

D’Alessandria C, Malviya G, Viscido A, Aratari A, Maccioni F, Amato A, et al. Use of a 99mTc labeled anti-TNFalpha monoclonal antibody in Crohn’s disease: in vitro and in vivo studies. Q J Nucl Med Mol Imaging 2007;51:334–42.PubMed

46.

Cipollone F, Fazia M, Mezzetti A. Novel determinants of plaque instability. J Thromb Haemost 2005;3:1962–75.CrossRefPubMed

47.

Rudd JH, Hyafil F, Fayad ZA. Inflammation imaging in atherosclerosis. Arterioscler Thromb Vasc Biol 2009;29:1009–16.CrossRefPubMed

48.

Breyholz HJ, Wagner S, Levkau B, Schober O, Schäfers M, Kopka K. A 18F-radiolabeled analogue of CGS 27023A as a potential agent for assessment of matrix-metalloproteinase activity in vivo. Q J Nucl Med Mol Imaging 2007;51:24–32.PubMed

49.

Schäfers M, Riemann B, Kopka K, Breyholz HJ, Wagner S, Schäfers KP, et al. Scintigraphic imaging of matrix metalloproteinase activity in the arterial wall in vivo. Circulation 2004;109:2554–9.CrossRefPubMed

50.

Kolodgie F, Edwards S, Petrov A, Sachleben R, Hartung D, Weber DK. Noninvasive detection of matrix metalloproteinase upregulation in experimental atherosclerotic lesions and its abrogation by dietary modification [abstract]. Circulation 2001;104:694.CrossRef

51.

Zhang J, Nie L, Razavian M, Ahmed M, Dobrucki LW, Asadi A, et al. Molecular imaging of activated matrix metalloproteinases in vascular remodeling. Circulation 2008;118:1953–60.CrossRefPubMed

52.

Fujimoto S, Hartung D, Ohshima S, Edwards DS, Zhou J, Yalamanchili P, et al. Molecular imaging of matrix metalloproteinase in atherosclerotic lesions: resolution with dietary modification and statin therapy. J Am Coll Cardiol 2008;52:1847–57.CrossRefPubMed

53.

Lancelot E, Amirbekian V, Brigger I, Raynaud JS, Ballet S, David C, et al. Evaluation of matrix metalloproteinases in atherosclerosis using a novel noninvasive imaging approach. Arterioscler Thromb Vasc Biol 2008;28:425–32.CrossRefPubMed

Titel: Imaging with radiolabelled anti-membrane type 1 matrix metalloproteinase (MT1-MMP) antibody: potentials for characterizing atherosclerotic plaques
verfasst von: Yuji Kuge
Nozomi Takai
Yuki Ogawa
Takashi Temma
Yan Zhao
Kantaro Nishigori
Seigo Ishino
Junko Kamihashi
Yasushi Kiyono
Masashi Shiomi
Hideo Saji
Publikationsdatum: 01.11.2010
Verlag: Springer-Verlag
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 11/2010
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-010-1521-2